Brendan Blumenstiel
About Brendan Blumenstiel
Brendan Blumenstiel is the Director of Genomics Research and Development at the Broad Institute of MIT and Harvard, where he has worked since 2003. He has held various positions within the institute, including Manager of Medical & Cancer Sequencing Technology Development and Associate Director.
Work at Broad Institute
Brendan Blumenstiel has been associated with the Broad Institute of MIT and Harvard since 2003. He began his career there as a Coordinator for Genotyping Technologies, a position he held until 2006. Following this role, he served as the Genetic Analysis Technology Development Manager from 2006 to 2009. In 2009, he transitioned to the Medical & Cancer Sequencing Technology Development Manager role, where he worked for 15 years. In 2016, he became the Associate Director, and in 2018, he was promoted to Director of Genomics Research and Development, where he continues to contribute to advancements in genomics.
Education and Expertise
Brendan Blumenstiel earned a Bachelor of Science degree in Biology from The Colorado College, where he studied from 1994 to 1998. His educational background has provided a strong foundation for his work in genomics and technology development. His expertise encompasses various aspects of genetic analysis and sequencing technologies, reflecting his extensive experience in the field.
Background in Genomics
Brendan Blumenstiel's career in genomics began with his role at the Broad Institute, where he has progressively advanced through various positions since 2003. His background includes significant experience in managing technology development projects related to medical and cancer sequencing. His work has contributed to the evolution of genomic research methodologies and applications.
Career Progression
Brendan Blumenstiel has experienced a steady career progression at the Broad Institute. Starting as a Coordinator in 2003, he moved through roles of increasing responsibility, including Genetic Analysis Technology Development Manager and Medical & Cancer Sequencing Technology Development Manager. His current position as Director of Genomics Research and Development reflects over two decades of commitment to the field.